Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) engages Abcam to make reagents required for the immunoassay version of its PromarkerD predictive blood test
- The test is used to detect kidney disease early in patients with type two diabetes
- Abcam will produce reagents such as synthetic protein standards and antibodies used to identify protein biomarkers of the disease in patients’ blood
- PIQ’s managing director Richard Lipscombe says the company’s commercialisation strategy for the test is on track
- Shares are up by 8.8 per cent to $1.11 each late in the session on Thursday
Proteomics International Laboratories (PIQ) has engaged global life science company Abcam to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test.
The test is used to detect kidney disease early in patients with type two diabetes and is designed for use on standard platforms found in most clinical pathology laboratories.
Under a commercial free-for-service agreement, Abcam will produce reagents, including synthetic protein standards and antibodies used to detect protein biomarkers associated with diabetic kidney disease in patients’ blood.
The companies recently finished producing recombinant versions of the revenant antibodies, with the work expected to result in a stable, more consistent product in the long-term and improve scale-up to secure future supply chains.
PIQ Managing Director Richard Lipscombe said in light of the deal, Proteomics’ commercialisation strategy for the test was on track.
“Having recently achieved ISO 13485 registration for our organisation, which enables internationally certified manufacture of the PromarkerD immunoassay, we are now building our production capacity to meet the anticipated worldwide demand for the PromarkerD test,” Dr Lipscombe said.
“By engaging global manufacturing partners such as Abcam, who are experts in the manufacturing processes we require, we are building a robust framework that will help accelerate the worldwide roll-out of PromarkerD, and also facilitate the future commercialisation of our exciting pipeline of diagnostics under development.”
Shares in Proteomics were up by 8.8 per cent to $1.11 each at 4:07 pm AEST.
